GUD vs. TLRY, CRON, THCX, WEED, ACB, FIRE, EPI, OGI, ICC, and CPH
Should you be buying Knight Therapeutics stock or one of its competitors? The main competitors of Knight Therapeutics include Tilray Brands (TLRY), Cronos Group (CRON), Hydropothecary (THCX), Canopy Growth (WEED), Aurora Cannabis (ACB), Supreme Cannabis (FIRE), ESSA Pharma (EPI), Organigram (OGI), ICC Labs (ICC), and Cipher Pharmaceuticals (CPH). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Knight Therapeutics (TSE:GUD) and Tilray Brands (TSE:TLRY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, community ranking, media sentiment, dividends, risk, profitability and institutional ownership.
Knight Therapeutics has a net margin of -5.25% compared to Tilray Brands' net margin of -47.35%. Knight Therapeutics' return on equity of -2.21% beat Tilray Brands' return on equity.
Knight Therapeutics has higher earnings, but lower revenue than Tilray Brands. Knight Therapeutics is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.
Knight Therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, Tilray Brands has a beta of 2.38, suggesting that its share price is 138% more volatile than the S&P 500.
Knight Therapeutics received 110 more outperform votes than Tilray Brands when rated by MarketBeat users. Likewise, 74.32% of users gave Knight Therapeutics an outperform vote while only 0.00% of users gave Tilray Brands an outperform vote.
Knight Therapeutics currently has a consensus price target of C$6.75, indicating a potential upside of 18.21%. Tilray Brands has a consensus price target of C$2.95, indicating a potential upside of 16.14%. Given Knight Therapeutics' higher possible upside, research analysts plainly believe Knight Therapeutics is more favorable than Tilray Brands.
In the previous week, Tilray Brands had 2 more articles in the media than Knight Therapeutics. MarketBeat recorded 3 mentions for Tilray Brands and 1 mentions for Knight Therapeutics. Knight Therapeutics' average media sentiment score of 0.00 equaled Tilray Brands'average media sentiment score.
13.7% of Knight Therapeutics shares are held by institutional investors. Comparatively, 12.2% of Tilray Brands shares are held by institutional investors. 46.4% of Knight Therapeutics shares are held by insiders. Comparatively, 1.2% of Tilray Brands shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Knight Therapeutics beats Tilray Brands on 11 of the 16 factors compared between the two stocks.
Get Knight Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GUD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Knight Therapeutics Competitors List
Related Companies and Tools
